Insights
Search Results
Client Highlights
8.06.26
Wilson Sonsini Advises AiDASH on $350 Million Acquisition by Schneider Electric
On July 30, 2026, Schneider Electric, a global energy technology company, announced it has entered a definitive agreement to acquire AiDASH, a cloud-native software company that provides AI-driven vegetation, asset, and climate risk intelligence to utilities and other critical infrastructure operators, in an all-cash transaction with implied enterprise value of $350 million. Wilson Sonsini Goodrich & Rosati is advising AiDASH on the transaction.
Client Highlights
7.29.26
Wilson Sonsini Advises DroneDeploy on $845 Million Acquisition by Procore Technologies
On July 29, 2026, Procore Technologies, a global provider of construction management software, announced it has entered into a definitive agreement to acquire DroneDeploy, a robotics and visual intelligence platform. Procore will acquire DroneDeploy for approximately $845 million in cash, subject to customary purchase price adjustments. Wilson Sonsini Goodrich & Rosati is advising DroneDeploy on the transaction
Client Highlights
6.30.26
Wilson Sonsini Advises Cognite, Major Shareholders on $3.1 Billion Sale to Schneider Electric
On June 30, 2026, Aker ASA (Aker) and the other shareholders of Cognite announced that they have entered into an agreement to sell 100 percent of the shares in Cognite Holding B.V. (Cognite) to Schneider Electric based on an enterprise value of US$3.1 billion. Wilson Sonsini Goodrich & Rosati’s cross-border tech M&A team advised Cognite and its major shareholders, including Aker, TCV, and Accel, on the transaction.
Client Highlights
6.05.26
Wilson Sonsini Advises SewerAI on Strategic Investment
On June 2, 2026, SewerAI, a leading AI platform for sewer and underground infrastructure intelligence, announced a major strategic investment led by JMI Equity, a leading growth equity software investor based in the greater Washington, D.C., area and San Diego, with continued participation from Innovius Capital, Epic Ventures, and Bentley Systems. Wilson Sonsini Goodrich & Rosati advised SewerAI on the transaction.
Client Highlights
6.03.26
Wilson Sonsini Advises Asana on Acquisition of StackAI
On May 28, 2026, Asana, Inc., the operating system for human-agent teams, announced that it has completed the acquisition of StackAI, a no-code AI workflow platform that enables companies to design, test, deploy, and govern custom AI agents and intelligent automation of business-critical workflows. Wilson Sonsini Goodrich & Rosati advised Asana on the transaction.
The StackAI platform connects workflows, data, and actions across enterprise systems such as ERP, CRM, and ITSM to automate operational processes like customer support, IT service requests, compliance workflows, and broader cross-functional business operations. Based in San Francisco, the company has built an impressive track record with customers across financial services, healthcare, and professional services—industries that demand the highest security, reliability, and enterprise-grade governance. Bringing StackAI and Asana together pairs cross-system execution with the platform where teams already plan and run their work alongside the context, ownership, and history of every project.
The Wilson Sonsini team that advised Asana on the transaction was led by Rich Mullen and Kaleigh Hawkins-Schulz and also included:
The StackAI platform connects workflows, data, and actions across enterprise systems such as ERP, CRM, and ITSM to automate operational processes like customer support, IT service requests, compliance workflows, and broader cross-functional business operations. Based in San Francisco, the company has built an impressive track record with customers across financial services, healthcare, and professional services—industries that demand the highest security, reliability, and enterprise-grade governance. Bringing StackAI and Asana together pairs cross-system execution with the platform where teams already plan and run their work alongside the context, ownership, and history of every project.
The Wilson Sonsini team that advised Asana on the transaction was led by Rich Mullen and Kaleigh Hawkins-Schulz and also included:
Client Highlights
6.01.26
Firm Advises Edgewise Therapeutics on Its Sale of Sevasemten for up to $2.65 Billion
On June 1, 2026, Edgewise Therapeutics, a leading muscle disease biopharmaceutical company, announced that it has entered into a definitive agreement under which Servier, an independent international pharmaceutical group governed by a foundation, will acquire sevasemten, an orally administered fast skeletal myosin inhibitor in late-stage clinical trials in Becker and Duchenne muscular dystrophies, and Edgewise's muscular dystrophy business for $1.55 billion in upfront cash consideration and up to $1.1 billion in additional milestone payments, for aggregate potential consideration of up to $2.65 billion. The transaction strengthens Edgewise’s balance sheet, providing enhanced financial flexibility and sharpening the company’s strategic focus to accelerate and unlock the full potential of its cardiovascular pipeline. Wilson Sonsini Goodrich & Rosati advised Edgewise on the transaction.
Client Highlights
4.06.26
Wilson Sonsini Advises Soleno Therapeutics on $2.9 Billion Acquisition by Neurocrine
On April 6, 2026, Neurocrine Biosciences and Soleno Therapeutics announced that Neurocrine has entered into a definitive agreement to acquire Soleno for $53.00 per share in cash, representing a total transaction equity value of $2.9 billion. Wilson Sonsini Goodrich & Rosati is advising Soleno on the transaction.
Client Highlights
3.27.26
Wilson Sonsini Advises Reltio on Acquisition by SAP
On March 27, 2026, SAP, a global leader in enterprise applications and business AI, announced its acquisition of Reltio, a leading master data management (MDM) software provider, to help customers make their SAP and non-SAP enterprise data AI-ready. Terms of the deal were not disclosed. Wilson Sonsini Goodrich & Rosati advised Reltio on the transaction.
Client Highlights
2.23.26
Firm Advises Arcellx on $7.8 Billion Acquisition by Gilead
On February 23, 2026, Gilead Sciences announced that it has entered into a definitive agreement to acquire Arcellx, a biotechnology company focused on delivering a new class of innovative immunotherapies for patients with cancer and other incurable diseases, for $115 per share in cash at closing and one contingent value right of $5 per share, which represents an implied equity value of $7.8 billion payable at closing. Wilson Sonsini Goodrich & Rosati advised Arcellx on the transaction.
Client Highlights
2.19.26
Wilson Sonsini Advises Griptape on Acquisition by Foundry
On February 18, 2026, Foundry, a leading developer of creative software for the media and entertainment industry, announced the completion of its acquisition of Griptape, a pioneer in enterprise-grade AI orchestration. Wilson Sonsini Goodrich & Rosati advised Griptape on the transaction.
As described by Foundry, the acquisition accelerates Foundry's AI strategy, adding critical orchestration capabilities to complement the AI-powered features in Foundry's product portfolio. It represents the next evolution of this strategy, enabling studios to orchestrate multiple AI models and agents within secure, professional workflows that connect seamlessly with Foundry's existing creative toolsets. As studios shift from experimentation to everyday production use, the need for better control of AI models has become critical. Griptape enables controlled access to rapidly evolving open-source and commercial AI models in a user-friendly framework, while balancing the strict security and traceability required by major production environments.
As described by Foundry, the acquisition accelerates Foundry's AI strategy, adding critical orchestration capabilities to complement the AI-powered features in Foundry's product portfolio. It represents the next evolution of this strategy, enabling studios to orchestrate multiple AI models and agents within secure, professional workflows that connect seamlessly with Foundry's existing creative toolsets. As studios shift from experimentation to everyday production use, the need for better control of AI models has become critical. Griptape enables controlled access to rapidly evolving open-source and commercial AI models in a user-friendly framework, while balancing the strict security and traceability required by major production environments.
Client Highlights
2.05.26
Wilson Sonsini Advises SpyGlass Pharma on $150 Million IPO
On February 5, 2026, SpyGlass Pharma, Inc., a late-stage biopharmaceutical company, announced the pricing of its initial public offering of 9,375,000 shares of its common stock at a public offering price of $16.00 per share. The aggregate gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by SpyGlass Pharma, are expected to be approximately $150 million. Wilson Sonsini Goodrich & Rosati advised SpyGlass Pharma on the transaction.
SpyGlass Pharma has granted the underwriters a 30-day option to purchase up to an additional 1,406,250 shares of common stock at the initial public offering price, less underwriting discounts and commissions. All shares of common stock are being offered by SpyGlass Pharma. SpyGlass Pharma’s common stock is expected to begin trading on the Nasdaq Global Select Market on February 6, 2026, under the ticker symbol “SGP.” The offering is expected to close on February 9, 2026, subject to the satisfaction of customary closing conditions.
The Wilson Sonsini team that advised SpyGlass Pharma includes:
SpyGlass Pharma has granted the underwriters a 30-day option to purchase up to an additional 1,406,250 shares of common stock at the initial public offering price, less underwriting discounts and commissions. All shares of common stock are being offered by SpyGlass Pharma. SpyGlass Pharma’s common stock is expected to begin trading on the Nasdaq Global Select Market on February 6, 2026, under the ticker symbol “SGP.” The offering is expected to close on February 9, 2026, subject to the satisfaction of customary closing conditions.
The Wilson Sonsini team that advised SpyGlass Pharma includes: